CN103356681B - The application of Houttuynoid A in preparation treatment myocardial ischemia drug - Google Patents
The application of Houttuynoid A in preparation treatment myocardial ischemia drug Download PDFInfo
- Publication number
- CN103356681B CN103356681B CN201310258042.0A CN201310258042A CN103356681B CN 103356681 B CN103356681 B CN 103356681B CN 201310258042 A CN201310258042 A CN 201310258042A CN 103356681 B CN103356681 B CN 103356681B
- Authority
- CN
- China
- Prior art keywords
- myocardial ischemia
- houttuynoid
- application
- preparation treatment
- houttuynoida
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Do you the invention provides Houttuynoid? the application of A in preparation treatment or prevention myocardial ischemia drug.The Houttuynoid that the present invention relates to? A belongs to first public preparing the purposes in medicaments for resisting myocardial ischemia, because framework types belongs to brand-new framework types, and its inhibit activities for myocardial ischemia is unexpectedly strong, there is not the possibility being provided any enlightenment by other compounds, possessing outstanding substantive distinguishing features, for resisting myocardial ischemia, obviously there is significant progress simultaneously.
Description
Technical field
The present invention relates to the application of HouttuynoidA in preparation treatment or prevention myocardial ischemia drug.
Background technology
The present inventor is found by a large amount of experiments, and HouttuynoidA has the/pharmacological action of reperfusion injury that resists myocardial ischemia, and has the medical usage of prevention or treatment myocardial ischemia disease.
The compound H outtuynoidA that the present invention relates to is one and delivers (Chen in 2012, S.D.etal., 2012.HouttuynoidA-E, Anti-HerpesSimplexVirusActiveFlavonoidswithNovelSkeleton sfromHouttuyniacordata.OrganicLetters14 (7), 17724 – 1775.) New skeleton compound, this compound has brand-new framework types, current purposes only relates to anti-herpes simplex virus activity (Chen, S.D.etal., 2012.HouttuynoidA-E, Anti-HerpesSimplexVirusActiveFlavonoidswithNovelSkeleton sfromHouttuyniacordata.OrganicLetters14 (7), 17724 – 1775.), the HouttuynoidA that the present invention relates to is belonged to first public preparing the purposes in medicaments for resisting myocardial ischemia, because framework types belongs to brand-new framework types, and its inhibit activities for myocardial ischemia is unexpectedly strong, there is not the possibility being provided any enlightenment by other compounds, possesses outstanding substantive distinguishing features, for resisting myocardial ischemia, obviously there is significant progress simultaneously.
Summary of the invention
The invention provides the application in the medicine of HouttuynoidA preparation treatment or prevention Ischemic/reperfusion.
The present inventor demonstrates by the experiment in detailed description of the invention the effect that HouttuynoidA has treatment or prevention myocardial ischemia drug disease.
Described compound H outtuynoidA structure is as shown in formula I:
The HouttuynoidA that the present invention relates to belongs to first public preparing the purposes in medicaments for resisting myocardial ischemia, because framework types belongs to brand-new framework types, and its inhibit activities for myocardial ischemia is unexpectedly strong, there is not the possibility being provided any enlightenment by other compounds, possessing outstanding substantive distinguishing features, for resisting myocardial ischemia, obviously there is significant progress simultaneously.
Detailed description of the invention
The preparation method of compound H outtuynoidA involved in the present invention is see document (Chen, S.D.etal., 2012.HouttuynoidA-E, Anti-HerpesSimplexVirusActiveFlavonoidswithNovelSkeleton sfromHouttuyniacordata.OrganicLetters14 (7), 17724 – 1775.).
The present invention is further detailed explanation by the following examples, but protection scope of the present invention is not by any restriction of specific embodiment, but be limited by claim.
Embodiment 1: the preparation of compound H outtuynoidA tablet involved in the present invention:
Get 20 g of compound HouttuynoidA, add the customary adjuvant 180 grams preparing tablet, mixing, conventional tablet presses makes 1000.
Embodiment 2: the preparation of compound H outtuynoidA capsule involved in the present invention:
Get 20 g of compound HouttuynoidA, add prepare capsule customary adjuvant as starch 180 grams, mixing, encapsulatedly makes 1000.
Its pharmaceutically active is further illustrated below by pharmacodynamic experiment.
Experimental example: HouttuynoidA is on the impact of myocardial ischemia/reperfusion injury in rats
(1) experiment material: SD rat, male and female dual-purpose, body weight 190 ~ 210g.
(2) method and result
1) experimental technique
The acute myocardial ischemia experiment of pituitrin induction: rat is divided into 5 groups at random: positive drug control group, model control group, administration group 3 groups, often organizes 8.Administration group gastric infusion, positive drug control group and model control group give the distilled water gavage of consubstantiality accumulated amount every day, the continuous gavage 7d of each group.All after the 7th day gavage, 1.5 ~ 2.0h lumbar injection pentobarbital sodium 30mg/kg anaesthetizes, and adopts MS2302 multimedia biological signal collecting analytical system to continue record standard II lead electrocardiogram.The Electrocardiographic change of record 15min continuously after positive drug control group, model control group and administration group sublingual vein injection of pituitrin 5IU/kg (complete in 5s, positive drug control group is 10min lumbar injection nitroglycerin 5mg/kg before injection of pituitrin) 10min.If there is one of following change in electrocardiogram: T ripple is low flat, two-way, and be inverted, ST section level moves down >=0.05mV, gives note 1 point.Finally analyze the total score of every rat, as reduced after medication score, prompting myocardial ischemia is improved.The impact of medicine on heart rate is represented with changes in heart rate percentage rate before and after injection of pituitrin.
Cardiac muscle ischemia resisting reperfusion injury experiment: rat is divided into 5 groups at random: positive drug control group, model control group, administration group 3 groups, often organizes 8.Administration group gastric infusion, positive drug control group and model control group give the distilled water gavage of consubstantiality accumulated amount every day, the continuous gavage 7d of each group.Record standard II lead electrocardiogram after rats by intraperitoneal injection pentobarbital sodium 30mg/kg anaesthetizes.Tracheal intubation, meets artificial respirator (1.0mlg
-1min
-1), thoracic cavity is opened at 4th ~ 5 intercostals, expose heart, at pulmonary conus left border, left auricle lower edge 1mm place is with 320 silk thread ligation ramus descendens anterior arteriae coronariae sinistraes (positive drug control group 3min sublingual vein before following coronary artery occlusion injects Propranolol 1.0mg/kg).After ligation 30min, cut off ligature, fill with 30min again.Quick taking-up heart, rinses well with 0.9% sodium chloride.Myocardium sheet is placed in the TTC solution of 1%, in 37 DEG C of hatching 5min.Rinse with water immediately after dyeing and remove dyestuff unnecessary on myocardium sheet.Cut off the non-infarcted region cardiac muscle that each myocardium sheet is colored, undyed infarcted myocardium and ischemic myocardium are weighed.
Hemodynamics is tested: rat is divided into 5 groups at random: positive drug control group, model control group, administration group 3 groups, often organizes 8.Administration group gastric infusion, positive drug control group and model control group give the distilled water gavage of consubstantiality accumulated amount every day, the continuous gavage 5d of each group.Within 6th day, lumbar injection urethane 10mg/kg anaesthetizes.Record standard II lead electrocardiogram.Longitudinally cut right skin of neck, be separated right common carotid artery, insert the left ventricular catheter being full of heparin 0.9% sodium chloride, conduit is slowly inserted left ventricular cavity.Cut left lower extremity inside skin, be separated femoral artery, insert ductus arteriosus.Cut-in pressure transducer, transports to multimedia bio signal monitor signal and observes.After balance 30min, each hemodynamic index before record administration.
So data all represent with x ± s, experimental group and the matched group data analysis sided t of two sample averages are checked.
2) result
Ischemia/reperfusion injury experimental result shows, under administration group, positive drug control group, model control group myocardial infarction and ligature, myocardial Mass Measured percentage ratio is respectively in table 1.
Table 1HouttuynoidA is on the impact of scheming weight ratio under myocardial infarction and ligature
Compare with model comparison, * * p<0.01, * p<0.05
HouttuynoidA on the impact of the acute myocardial ischemia that pituitrin causes in table 2.
Table 2HouttuynoidA is on the impact of the acute myocardial ischemia that pituitrin causes
Compare with model comparison, * * p<0.01, * p<0.05
Conclusion: HouttuynoidAA can reduce the generation of myocardial infarction, and HouttuynoidA obviously can change the change of electrocardio degree, does not change heart rate.More than experiment can illustrate, HouttuynoidA can prevention and therapy myocardial ischemia.
Claims (1)
1.HouttuynoidA preparation treatment or prevention myocardial ischemia drug in application, described compound H outtuynoidA structure as
formula Ishown in:
formula I.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310258042.0A CN103356681B (en) | 2013-06-24 | 2013-06-24 | The application of Houttuynoid A in preparation treatment myocardial ischemia drug |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310258042.0A CN103356681B (en) | 2013-06-24 | 2013-06-24 | The application of Houttuynoid A in preparation treatment myocardial ischemia drug |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103356681A CN103356681A (en) | 2013-10-23 |
| CN103356681B true CN103356681B (en) | 2015-11-25 |
Family
ID=49359497
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310258042.0A Expired - Fee Related CN103356681B (en) | 2013-06-24 | 2013-06-24 | The application of Houttuynoid A in preparation treatment myocardial ischemia drug |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103356681B (en) |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102670583A (en) * | 2012-06-11 | 2012-09-19 | 新疆德泓生物科技有限公司 | Application of flavonoids in moldavica dragonhead in the preparation of myocardial ischemic antagonist |
-
2013
- 2013-06-24 CN CN201310258042.0A patent/CN103356681B/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN103356681A (en) | 2013-10-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103638012B (en) | Application of Myrtucommuacetalone in medicine for treatment of myocardial ischemia | |
| CN103768051B (en) | The application of Eryngiolide A in preparation treatment myocardial ischemia drug | |
| CN103520170B (en) | Kadcoccitones A application in preparation treatment myocardial ischemia drug | |
| CN103393703B (en) | The application of Houttuynoid B in preparation treatment myocardial ischemia drug | |
| CN103356681B (en) | The application of Houttuynoid A in preparation treatment myocardial ischemia drug | |
| CN103381182B (en) | The application of Houttuynoid C in preparation treatment myocardial ischemia drug | |
| CN103356647B (en) | The application of Chukrasone A in preparation treatment myocardial ischemia drug | |
| CN105412073A (en) | Application of Spirooliganone B in preparation of myocardial ischemia treatment drug | |
| CN103356595B (en) | The application of Chukrasone B in preparation treatment myocardial ischemia drug | |
| CN103751182B (en) | The application of a kind of compound in treatment myocardial ischemia drug | |
| CN103479609A (en) | Application of Scopariusins in preparation of myocardial ischemia treatment medicines | |
| CN105412068A (en) | Application of Rearranged abietane diterpenoid in preparation of drugs for treating myocardial ischemia | |
| CN105380940A (en) | Use of Rhodomicranols B in preparation of drug for treating myocardial ischemia | |
| CN105250269A (en) | Application of Nagelamides X in preparation of drug for treating myocardial ischemia | |
| CN105168207A (en) | Medicine for treating myocardial ischemia and application thereof | |
| CN102861035B (en) | Application of Gypensapogenin B in medicine for treating myocardial ischemia | |
| CN102988351A (en) | Application of Aphanamixoid A for preparing medicine for treating myocardial ischemia | |
| CN106344579A (en) | Application of Fistulains A in drugs for myocardial ischemia treatment | |
| CN103340886A (en) | Application of Polyflavanostilbene A in preparation of medicine for treating myocardial ischemia | |
| CN103463008A (en) | Application of racemosins A in preparation of medicine treating myocardial ischemia | |
| CN103263424A (en) | Application of Myriberine A in preparation of medicine for treating myocardial ischemia | |
| CN103479620A (en) | Application of Neonectrolide A to in preparation of medicament for treating myocardial ischemia | |
| CN103610678B (en) | The application of Trigolutesins A in treatment myocardial ischemia drug | |
| CN103393657A (en) | Application of Sarcaboside A to medicament for treatment of myocardial ischemia | |
| CN103381178A (en) | Application of Houttuynoid D in drug for treatment of myocardial ischemia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| CB03 | Change of inventor or designer information |
Inventor after: Yang Guixia Inventor after: Zheng Xin Inventor after: Du Pingping Inventor before: Ding Shengyu |
|
| COR | Change of bibliographic data | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20151013 Address after: 261500, room 1, unit 1, building 301, community hospital of traditional Chinese medicine, three community hospital, East China Town, Gaomi City, Weifang, Shandong Applicant after: Yang Guixia Address before: 210009 Gulou District, Jiangsu, Nanjing Gu Ping Kong, No. 4 Applicant before: Ding Shengyu |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20151125 Termination date: 20160624 |